Additional file 3 of A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-α5 NAM (basmisanil) on intellectual disability associated with Down syndrome

Goeldner, Celia; Kishnani, Priya S.; Skotko, Brian G.; Casero, Julian Lirio; Hipp, Joerg F.; Derks, Michael; Hernandez, Maria-Clemencia; Khwaja, Omar; Lennon-Chrimes, Sian; Noeldeke, Jana; Pellicer, Sabine; Squassante, Lisa; Visootsak, Jeannie; Wandel, Christoph; Fontoura, Paulo; d’Ardhuy, Xavier Liogier

doi:10.6084/m9.figshare.19129022.v1

11689_2022_9418_MOESM3_ESM.doc (130 kB)

Additional file 3 of A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-α5 NAM (basmisanil) on intellectual disability associated with Down syndrome

journal contribution

posted on 2022-02-07, 04:30 authored by Celia Goeldner, Priya S. Kishnani, Brian G. Skotko, Julian Lirio Casero, Joerg F. Hipp, Michael Derks, Maria-Clemencia Hernandez, Omar Khwaja, Sian Lennon-Chrimes, Jana Noeldeke, Sabine Pellicer, Lisa Squassante, Jeannie Visootsak, Christoph Wandel, Paulo Fontoura, Xavier Liogier d’Ardhuy

Additional file 3. Primary and secondary assessment scales. Provides more detailed information on the scales, including the DS-CGI-I.

Funding

F. Hoffmann-La Roche

History

Usage metrics

Keywords

Down syndrome GABAA-α5 Cognition Adaptive behavior EEG

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Additional file 3 of A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-α5 NAM (basmisanil) on intellectual disability associated with Down syndrome

Funding

F. Hoffmann-La Roche

History

Usage metrics

Categories

Keywords

Licence

Exports